Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Sten Stovall

London, UK
Sten Stovall is a London-based editor and writer with 40 years of experience in the field of journalism, including more than 20 years with Reuters and eight years with The Wall Street Journal/Dow Jones Newswires. He also has wide radio and television reporting experience and a solid network of contacts in the biopharma world. Sten is part of our team of specialist reporters, generating insightful features and analysis about R&D, product development, regulatory issues and industry trends for publications such as "The Pink Sheet", Scrip and IN VIVO.
Advertisement
Set Alert for Articles By Sten Stovall

Latest From Sten Stovall

Shire CEO Says Lanadelumab Results Vindicate Dyax Buy, M&A Strategy

Shire's CEO is savoring a personal victory after Phase III data for lanadelumab in acute HAE replicated impressive Phase Ib trial results that underpinned his 2015 decision to buy Dyax.

Business Strategies Clinical Trials

Novo Nordisk CEO Puts Pricing On The Line

Lars Fruergaard Jørgensen, Novo Nordisk's CEO, says the group's pledge on price transparency, goals for improved outcomes and experimental use of digital health are commercially linked.

Commercial Companies

Ipsen's New CEO Targets At Least One New Drug Annually 'Forever'

The French pharma under its American CEO plans to transform itself through R&D and M&A, and promises to launch at least one new drug or new valuable indication every year - "forever".

Business Strategies Commercial

'Think Global, Act Local' - Novo Nordisk CEO To Empower Regions, Cut Red Tape

Novo Nordisk's new CEO says bureaucracy and centralized control hinder sales growth, so one of his three top priorities is to give regional centers more commercial autonomy.

Business Strategies Commercial

What Artificial Intelligence Brings To Drug Discovery – Sanofi Interview

By adding another AI deal to Sanofi's innovation quiver, the French group says it's widening its hunt to find single molecules that offer dual or multi-specific targeting to fight disease.

Commercial Companies

Quest To Use AI In Drug Discovery Joins Sanofi and Exscientia

Sanofi hopes to use Exscientia's artificial intelligence (AI) platform to develop bispecific-small-molecule drugs for diabetes and associated metabolic conditions.

Business Strategies Companies
See All
Advertisement
UsernamePublicRestriction

Register